MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
38.24
+0.02
+0.05%
After Hours: 38.24 0 0.00% 18:11 06/25 EDT
OPEN
38.28
PREV CLOSE
38.22
HIGH
39.28
LOW
37.98
VOLUME
2.67M
TURNOVER
--
52 WEEK HIGH
39.28
52 WEEK LOW
14.32
MARKET CAP
7.85B
P/E (TTM)
-13.7971
1D
5D
1M
3M
1Y
5Y
1D
10 mid-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 1d ago
Top Immunovant Insider Makes Notable Stock Move, Stirring Investor Buzz
TipRanks · 2d ago
Weekly Report: what happened at IMVT last week (0615-0619)?
Weekly Report · 3d ago
Immunovant (IMVT) Stock Could Be 14.1% Undervalued After Loss And Trial Updates
Simply Wall St · 5d ago
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
NASDAQ · 6d ago
Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed
Simply Wall St · 6d ago
Weekly Report: what happened at IMVT last week (0608-0612)?
Weekly Report · 06/15 09:23
A Look At Immunovant (IMVT) Valuation As IMVT 1402 Trial Engagement Lifts Investor Interest
Simply Wall St · 06/10 17:16
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.